Roswell Park is America's first cancer centre (1898), with strengths in immunotherapy and cell therapy manufacturing.
Roswell Park Comprehensive Cancer Center in Buffalo is America's first cancer centre, founded in 1898, and holds NCI comprehensive designation; its strengths are immunotherapy and cell therapy manufacturing. It runs GMP cell manufacturing, developed the SurVaxM glioblastoma vaccine, and is the origin of photodynamic therapy through Dougherty, with Candace S. Johnson, Renier J. Brentjens, Igor Puzanov, Eunice S. Wang, Pawel Kalinski and Robert A. Fenstermaker and Kara M. Kelly among the people OnCo lists, and Gilda Radner also linked. OnCo connects it to photoimmunotherapy and photodynamic therapy and to Generate:Biomedicines. Whether academic GMP capacity can lower the cost of cell therapies is the question its manufacturing programme tests. Its cell therapy and photodynamic programmes are listed below.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Roswell Park Comprehensive Cancer Center, including child institutions. 1,174 works · 16,051 citations · 65% open access · 14% clinical trials · 2% reviews.
Candace Johnson is a pharmacologist who has led America's oldest cancer centre since 2015.
Eunice Wang is an AML trialist who helped bring FLT3 and menin inhibitors to patients.
The Saturday Night Live star wrote about her ovarian cancer in It's Always Something and died at 42 in 1989. Her name lives on in Gilda's Club and the familial ovarian cancer registry at Roswell Park.
Led the first talimogene laherparepvec plus ipilimumab study and co-wrote the immune toxicity management guidelines.
Leads the COG Hodgkin lymphoma committee and the trials bringing brentuximab and nivolumab to children with the disease.
Pawel Kalinski is an immunologist reprogramming tumour microenvironments so T cells can enter.
Built one of the first CD19 CAR-T programmes and invented 'armoured' CAR-T cells that secrete cytokines.
Robert Fenstermaker invented SurVaxM, a survivin-targeted vaccine in late-stage trials for glioblastoma.